Venus Remedies has received the marketing approval from the Philippines, the second largest market in the Association of Southeast Asian Nations (ASEAN) bloc, for six key chemotherapy drugs.
Venus Remedies has secured the marketing authorisation for bortezomib cisplatin, doxorubicin, docetaxel, flurouracil and paclitaxel. With this, the pharma company has secured 525 marketing approvals for its oncology products across 76 countries.
The company has so far secured marketing approval for 52 products across various segments, presents immense opportunities for the company to expand its operations in the Asia Pacific region in general and Southeast Asia in particular through its elaborate range of drugs.
Catch all market action in our live blog
Venus Remedies has submitted dossiers to the health ministry of the Philippines for 45 more marketing authorisations, and most of these pending approvals are for oncology product.
"While oncology drugs account for 157 of our 205 marketing authorisations in the ASEAN region, we are banking on these product registrations from the Philippines to pave the way for faster approval of these drugs in other South east Asian countries as well. Consequently, we will further expand our operations to other ASEAN markets, reaffirming our commitment to provide advanced cancer treatment options with improved outcomes for patients," said Saransh Chaudhary, CEO of Venus Medicine Research Centre.
The company's oncology wing has also secured marketing approval from Myanmar for the chemotherapy drug oxaliplatin.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
